Drawing for SPAGEN

USPTO serial 78114048

SPAGEN

Reviewed by CopyMark Law Group

Status 605
Filing date
Status date
Registration date
—
Examiner
SWAIN, MICHELE LYNN
Law office
FILE REPOSITORY (FRANCONIA)

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with SPAGEN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Mark I. Peroff

G ROXANNE ELINGS GREENBERG TRAURIG21ST FL885 THIRD AVENEW YORK, NY 10022

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for the treatment of Alzheimer's disease, dementia, AIDS-related dementia, CNS, neuropathic pain, diabetic neuropathy, neurological disorders, neurodegenerative disorders, and/or depression; neuroprotective agentABANDONED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jun 24, 2003ABN5ABANDONMENT - AFTER PUBLICATION—
Nov 18, 2002MAILPAPER RECEIVED—
Oct 28, 2002ETOFEXTENSION OF TIME TO OPPOSE RECEIVED—
Sep 24, 2002PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 4, 2002NPUBNOTICE OF PUBLICATION—
Aug 20, 2002TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Jun 28, 2002CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jun 26, 2002DOCKASSIGNED TO EXAMINER—

Frequently asked questions

Related guidance